We are live on
!
Find out more
ADMA Biologics
ADMA
ADMA
55 hedge funds and large institutions have $115M invested in ADMA Biologics in 2018 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 18 increasing their positions, 3 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
500% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 3
244% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 9
62% more funds holding
Funds holding: 34 → 55 (+21)
48% more capital invested
Capital invested by funds: $78M → $115M (+$37.2M)
8.93% more ownership
Funds ownership: 46.16% → 55.09% (+8.9%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Holders
55
Holders Change
+21
Holders Change %
+61.76%
% of All Funds
1.26%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
31
Increased
18
Reduced
3
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
PA
Perceptive Advisors
New York
|
+$13.5M |
| 2 |
BC
Broadfin Capital
New York
|
+$12.6M |
| 3 |
BlackRock
New York
|
+$4.64M |
| 4 |
CCM
Consonance Capital Management
New York
|
+$4.59M |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$4.15M |
Top Sellers
| 1 |
HCM
Highbridge Capital Management
New York
|
-$1.44M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.01M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$435K |
| 4 |
Goldman Sachs
New York
|
-$429K |
| 5 |
Millennium Management
New York
|
-$220K |
